Searchable abstracts of presentations at key conferences in endocrinology

ea0050cmw5.3 | Workshop 5: How do I. . . (2) | SFEBES2017

How do I ... approach CVS surveillance in a patient with Turner Syndrome

Gravholt Claus H

New international clinical guidelines have just been published, based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus Meeting held in Cincinnati, Ohio, USA in July 2016. These guidelines were initiated and developed by ESE in Europe, and by PES in USA, with important contributions from ESHRE, Endocrine Society, ESC, AHA, Society for Endocrinology, and ESPE.Morbidity and...

ea0050cmw5.3 | Workshop 5: How do I. . . (2) | SFEBES2017

How do I ... approach CVS surveillance in a patient with Turner Syndrome

Gravholt Claus H

New international clinical guidelines have just been published, based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus Meeting held in Cincinnati, Ohio, USA in July 2016. These guidelines were initiated and developed by ESE in Europe, and by PES in USA, with important contributions from ESHRE, Endocrine Society, ESC, AHA, Society for Endocrinology, and ESPE.Morbidity and...

ea0063mte8 | (1) | ECE2019

Comorbidities in Turner Syndrome

Gravholt Claus H.

Treatment with growth hormone (GH) during childhood and adolescence allows a considerable gain in adult height. SHOX deficiency explains some of the phenotypic characteristics in TS, principally short stature. Puberty has to be induced in most cases, and female sex hormone replacement therapy should continue during adult years. These issues are normally dealt with by the paediatrician, but once a TS female enters adulthood it is less clear who should be the primary care giver....

ea0049gs1.1 | Guided session 1 | ECE2017

New international clinical practice guidelines for the care of girls and women with turner syndrome

Gravholt Claus H

Turner syndrome (TS) affects 25–50 per 100 000 females and can involve multiple organs through all stages of life, necessitating a multidisciplinary approach to care. Previous guidelines have highlighted this, but numerous important advances have been noted since their publication. These advances cover all specialty fields involved in the care of girls and women with TS. This new international guideline is based on an international effort that started with exploratory mee...

ea0032s4.2 | New advances in GPCRs in endocrinology | ECE2013

Biased agonism of the AT1 receptor: perspectives in drug discovery?

Hansen J H

The angiotensin II type 1 receptor (AT1R) belongs to the family of seven trans-membrane (7TM) receptors, also referred to as G-protein coupled receptors. The AT1R is the primary effector of the renin–angiotensin system, and serves as a key regulator of cardiovascular physiology. The importance of the receptor is clearly illustrated be the frequent use of AT1R blockers and ACE inhibitors in cardiovascular medicine. Upon binding of Ang II th...

ea0032s13.2 | Hormonal treatment in transition of patients with rare diseases (Supported by the <ulink url="http://www.eje-online.org/"><emphasis role="italic">European Journal of Endocrinology</emphasis></ulink>) | ECE2013

Transition of females with Turner syndrome

Gravholt Claus H

Treatment with GH during childhood and adolescence allows a considerable gain in adult height. SHOX deficiency explains some of the phenotypic characteristics in TS, principally short stature. Puberty has to be induced in most cases, and female sex hormone replacement therapy should continue during adult years. These issues are normally dealt with by the paediatrician, but once a TS female enters adulthood it is less clear who should be the primary care giver. Morbidity and mo...

ea0029oc19.1 | Cardiovascular Endocrinology | ICEECE2012

Both EPA/AA ratio and absolute AA levels constitute an independent risk factor for coronary atherosclerosis in type 2 diabetic patients

Nakamua T. , Maegawa H.

Background: N-3 polyunsaturated fatty acids (PUFA), such as α linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been shown to modify several key risk factors for cardiovascular disease, although n-6 PUFA arachidonic acid (AA) has important roles in inflammation. However, it is not clear whether the apparent protection of n-3 PUFA against cardiovascular disease has been found in diabetic patients.Methods: To clari...

ea0029p1135 | Neuroendocrinology | ICEECE2012

Effect of galanin on aromataze gene expression and estradiol 17-β concentrations in ventromedial and lateral hypothalamic area

Namdar F. , Khazali H.

The goal of this study was to determine whether galanin increase aromataze gene expressions and estradiol 17-β concentrations in ventromedial (VMH) and lateral hypothalamic area (LH). Forty rats were randomly divided into four groups. Animals in different groups were received either saline, 1, 2 or 4 ng galanin into their VMH and LH. After infusion of galanin, VMH and LH tissue were separated and homogenized. Homogenized sample were assayed for aromataze gene expression b...

ea0029p1280 | Obesity | ICEECE2012

Relationship between visceral fat and neck circumference in patients with metabolic syndrome

Gulmez H. , Kut A.

The metabolic syndrome is a combination of multi-factorial risk factors, which affects more people because of increased incidence of obesity and diabetes. The metabolic syndrome is one of the major health problems for the 21st century.In this study, we compared neck circumferences measurements with some of the metabolic and anthropometric measurements in patients presenting with complains of weight, and aimed to show the correlation between visceral fat ...